Related Experiment Video
Updated: Apr 22, 2026
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Successful treatment of Kaposiform hemangioendothelioma with everolimus
Teruaki Uno1, Shuichi Ito, Atsuko Nakazawa
1Children's Cancer Center, National Center for Child Health and Development, Setagaya, Tokyo, Japan.
Abstract:
There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE.
